Acceleron Pharma Inc.
ALK7:actriib heteromultimers and uses thereof
Last updated:
Abstract:
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.
Status:
Grant
Type:
Utility
Filling date:
18 Jan 2019
Issue date:
8 Jun 2021